Company Analysis
Sign in

Acurx Pharmaceuticals, Inc. (ACXP)

Nasdaq: ACXP · Pharmaceutical Preparations · Staten Island, NY · filing with the SEC since 2018
Full chart Alerts Compare
Grade5.4
◀ Past 4.2● Present 4.7▶ Future 6.6
6 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Income statement, as filed

In US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.
Income statement, by fiscal year, newest first
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Period endingDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020
Report filedMar 12, 2026Mar 17, 2025Mar 15, 2024Mar 15, 2023Mar 16, 2022·
Research and development1,834,5065,403,8366,043,5974,754,2712,030,1772,202,979
Selling, general and administrative····208,270·
General and administrative6,257,4778,719,391r8,534,1717,338,50510,784,0232,397,059
Total operating expenses8,091,98314,123,227r14,577,76812,092,77612,814,2004,600,038
Operating income-8,091,983-14,123,227····
Interest and investment income125,44520,124····
Income tax expense···0·0
Net income including non-controlling interests-7,966,538-14,103,103-14,577,768-12,092,776-12,747,697-4,600,038
Net income-7,966,538-14,103,103-14,577,768-12,092,776-12,747,697-4,600,038
Earnings per share, basic-5.32-17.45r-23.00b-22.40b-29.80b-14.80b
Earnings per share, diluted-5.32-17.45r-23.00b-22.40b-29.80b-14.80b
Weighted average shares, basic1,498,793808,168r633,579b540,821b426,794b309,544b
Weighted average shares, diluted1,498,793808,168r633,579b540,821b426,794b309,544b
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.Share counts and per-share figures are on the newest report's basis, after the 1-for-20 reverse split of Aug 2025.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Research and development spent on inventing what it sells nextus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative the cost of selling and of running the companyus-gaap:SellingGeneralAndAdministrativeExpense
General and administrative the cost of running the company itselfus-gaap:GeneralAndAdministrativeExpense
Total operating expenses the running costs togetherus-gaap:OperatingExpenses
Operating income profit from running the business, before interest and taxus-gaap:OperatingIncomeLoss
Interest and investment income what its cash and investments earnedus-gaap:InvestmentIncomeInterest
Income tax expense tax charged on the period's profitus-gaap:IncomeTaxExpenseBenefit
Net income including non-controlling interests the whole group's profit, minority holders' share includedus-gaap:ProfitLoss
Net income the profit or loss that belongs to the company's shareholdersus-gaap:NetIncomeLoss
Earnings per share, basic net income per share outstandingus-gaap:EarningsPerShareBasic
Earnings per share, diluted net income per share, counting every share that could be issuedus-gaap:EarningsPerShareDiluted
Weighted average shares, basic the average count of shares outstandingus-gaap:WeightedAverageNumberOfSharesOutstandingBasic
Weighted average shares, diluted the average count with every share that could be issuedus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
SI Assistanton ACXP · research, not advice